Viswa Colluru, Enveda Biosciences CEO March 31, 2026 07:00 AM EDTUpdated 09:14 AM R&D AI Exclusive: In promising early readout, Enveda shows Dupixent-rivaling potential in atopic dermatitis Andrew Dunn Senior Biopharma Correspondent Envedas first-ever clinical readout places its lead eczema drug among the top candidates in an increasingly crowded race to follow the blockbuster immunology treatment Dupixent
The compound corresponds to a small fragment of the hGH sequence responsible for stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage), while avoiding the insulin-resistance and tissue-growth effects associated with full-length hGH
When women stop menstruating, its easier to maintain healthy iron levels, and headaches can decrease
Together, they address healing from two directions: one works where you are hurt, the other supports your whole body's repair response
BPC-157 upregulates VEGFR2 and modulates the nitric oxide and FAK-paxillin pathways